Uneingeschränkter Zugang

Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients

,

und

Martina Vrankar

Martina Vrankar

| 20. Nov. 2019

Radiology and Oncology's Cover Image

Radiology and Oncology

Band 53 (2019): Heft 4 (December 2019)

Über diesen Artikel

Vorheriger Artikel

Nächster Artikel

Zitieren

Teilen

Article Category: Research Article

Online veröffentlicht: 20. Nov. 2019

Seitenbereich: 453 - 458

Eingereicht: 01. Aug. 2019

Akzeptiert: 30. Aug. 2019

DOI: https://doi.org/10.2478/raon-2019-0053

© 2019 Karmen Stanic, Nina Turnsek, Martina Vrankar, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Diagram of division: From 7th to 8th TNM classification with incorporation of EGFR mutation status.EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

Survival curves of different M categories according to EGFR mutation status based on 8th TNM classification.EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

Baseline characteristics of patients by EGFR mutation status

Characteristics	All	EGFR-wt		EGFR-m
	n	n	(%)	n	(%)	p
All patients	355	266	75	89	25
Age (years)
median	64.4	63.5	65.6	65.6		0.98
range	25-88	25–87	25–87	36–88
Gender
female	165	107	40.2	58	65.2	< 0.001
male	190	159	59.8	31	34.8
Smoking status						< 0.001
current	142	132	49.6	10	11.2
former	101	81	30.5	20	22.5
never	95	40	15.0	55	61.8
unknown	17	13	4.9	4	4.5
Histology
adenocarcinoma	309	232	87.2	77	86.2	0.86
non-small cell lungcancer, NOS	46	34	12.8	12	13.5
Metastatic sites*
Brain	86	61	22.9	25	28.1	0.33
Bone	151	104	39.1	47	52.8	0.02
Lung	157	106	39.8	51	57.3	0.01
Pleura	115	83	31.2	32	36.0	0.48
Liver	55	40	15.0	15	16.9	0.68
Adrenal gland	49	43	16.2	6	6.7	0.02
Distant lymph nodes	55	46	17.3	9	10.1	0.10
Other sites	40	34	12.8	6	6.7	0.11

Site specific median overall survival (mOS) according to EGFR mutation status

Metastatic site	Patients		mOS

	n	all	EGFR-m	EGFR-wt	p
Brain	86	8.1	14.9	7.1	0.003
Bone	151	9.4	21.3	6.7	< 0.001
Lung	157	11.9	20.2	8.3	0.002
Pleura	115	8.8	20.6	6.5	< 0.001
Liver	55	5.6	10.4	5.5	0.245
Adrenal gland	49	5.2	4.9	5.5	0.595
Distant lymph nodes	55	6.2	13.0	5.5	0.237
Other sites	40	8.9	14.9	8.4	0.156

M descriptors for 7th and 8th TNM classification according to EGFR mutation status and their median overall survival (mOS) in months

	7^th TNM classification

M descriptor		EGFR-m			EGFR-wt

	n	n	mOS	n	mOS	p
M1a	78	17	22.4	61	10.7	0.025
M1b	252	72	18.8	205	7.9	< 0.001
All	355	89	20.6	266	8.3	< 0.001

8^th TNM classification		EGFR-m			EGFR-wt

M1a	78	17	22.4	61	10.7	0.025
M1b	37	5	39.2	32	14.4	0.082
M1c	240	67	18.8	173	6.6	< 0.001
All	355	89	20.6	266	8.3	< 0.001

Overall survival of EGFR-m compared to EGFR-wt patients based on the M1b status in 7th TNM classification for single and multiple metastatic sites/organs

Metastatic sites (old M1b only)	all	EGFR-m		EGFR-wt		p

	n	n	mOS	n	mOS
Single organ	72	14	32.5	58	11.5	< 0.001
Multiple organs	205	58	17.4	147	6.1	< 0.001
All	277	77	20.5	205	7.8	< 0.001

eISSN:: 1581-3207
Sprache:: Englisch

Zeitrahmen der Veröffentlichung:: 4 Hefte pro Jahr
Fachgebiete der Zeitschrift:: Medizin, Klinische Medizin, Radiologie, Allgemeinmedizin, Innere Medizin, Hämatologie, Onkologie

Zeitschrift RSS Feed